Form 4: Fennec Pharmaceuticals Director Rosty Raykov Reports Stock Sales
SEC Form 4 Filing
Director Rosty Raykov of Fennec Pharmaceuticals reports the sale of common shares on January 6, 2025, according to a Form 4 filing.
Summary
- Rosty Raykov, a director of Fennec Pharmaceuticals, filed a Form 4 with the SEC.
- The filing reports the sale of 2,431 common shares at $6.08 per share on January 6, 2025, pursuant to a 10b5-1 plan dated December 14, 2023.
- Raykov also reports the sale of 7,569 common shares at $6.08 per share on January 6, 2025.
- Following these transactions, Raykov beneficially owns 83,863 common shares.
- The shares were acquired through the exercise of an option contract with a strike price of $2.36 on August 13, 2020.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard disclosure of stock sales by a company director. There is no indication of positive or negative sentiment related to the company's performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders of a publicly traded company buy or sell the company's securities. These filings provide transparency into the transactions of company directors and officers.
Stakeholder Impact
- The stock sales by a director may have a minor impact on shareholder confidence, depending on the context and the size of the transactions.
Key Dates
| Date | Description |
|---|---|
| August 13, 2020 | Shares acquired through the exercise of an option contract with strike price of $2.36. |
| December 14, 2023 | Date of the 10b5-1 plan under which shares were sold. |
| January 6, 2025 | Date of the reported stock sales. |
| January 7, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.